Mavacamten: Indications, Monitoring, and Practical Clinical Use in Obstructive Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, affecting approximately 1 in 500 people. While many patients remain asymptomatic, others develop significant symptoms due to obstruction of the left ventricular outflow tract (LVOT). Until recently, treatment options mainly focused on reducing symptoms with medications or relieving obstruction through invasive septal reduction procedures.

The introduction of mavacamten has changed the management of symptomatic obstructive HCM. Rather than simply controlling heart rate or contractility, mavacamten directly targets the underlying disease mechanism, making it the first disease-specific medical therapy approved for obstructive HCM.

This article reviews its mechanism of action, indications, patient selection, monitoring requirements, and practical clinical considerations.

---

What is Mavacamten?

Mavacamten is a first-in-class selective cardiac myosin inhibitor.

In obstructive hypertrophic cardiomyopathy, excessive interaction between actin and myosin causes hypercontractility, impaired ventricular relaxation, increased myocardial stiffness, and dynamic LVOT obstruction.

Mavacamten reduces excessive actin-myosin cross-bridge formation, allowing the heart muscle to contract more efficiently rather than excessively. This decreases LVOT obstruction while improving diastolic filling and overall cardiac performance.

Instead of treating only symptoms, mavacamten addresses the fundamental pathophysiology of obstructive HCM.

---

FDA-Approved Indication

Mavacamten is indicated for:

• Adults with symptomatic obstructive hypertrophic cardiomyopathy

• NYHA Class II or III symptoms

• Significant LVOT obstruction (typically gradient ≥50 mmHg at rest or with provocation)

• Patients who remain symptomatic despite maximally tolerated first-line medical therapy or who cannot tolerate conventional medications.

Current guidelines recommend careful patient selection using echocardiography before initiating therapy.

---

Which Patients Benefit Most?

Ideal candidates include patients with:

• Exertional dyspnea

• Chest discomfort

• Exercise intolerance

• Presyncope or syncope related to LVOT obstruction

• Persistent symptoms despite beta-blockers or verapamil

• Significant dynamic LVOT gradient

Many patients experience:

• Reduced symptoms

• Improved exercise capacity

• Lower LVOT gradients

• Better quality of life

• Reduced need for septal reduction therapy

---

Before Starting Mavacamten

A thorough baseline evaluation is essential.

Recommended assessment includes:

• Complete clinical history

• NYHA functional class

• Electrocardiogram

• Comprehensive echocardiography

• Left ventricular ejection fraction (LVEF)

• Resting and provoked LVOT gradients

• Medication review for potential drug interactions

Because mavacamten reduces myocardial contractility, baseline LVEF should be at least 55%.

Pregnancy should be excluded before treatment because fetal toxicity is a concern.

---

Monitoring During Therapy

Monitoring is the cornerstone of safe mavacamten therapy.

1. Echocardiography

The most important investigation.

Assess:

• LVEF

• LVOT gradient

• Mitral regurgitation

• Diastolic function

• Overall ventricular performance

---

2. Left Ventricular Ejection Fraction

This is the most critical safety parameter.

Treatment should not continue if:

LVEF falls below 50%.

Temporary interruption allows ventricular function to recover in most patients.

---

3. Clinical Monitoring

Evaluate patients for:

• Increasing fatigue

• Dyspnea

• Peripheral edema

• Orthopnea

• Weight gain

These symptoms may indicate excessive reduction in myocardial contractility.

---

4. Medication Review

Drug interactions can significantly alter mavacamten levels.

Particular attention should be paid to drugs affecting:

• CYP2C19

• CYP3A4

Avoid strong inhibitors or inducers whenever possible.

---

Echocardiographic Follow-up

Typical monitoring schedule includes:

Initial treatment:

Every 4–8 weeks while adjusting dosage.

Stable patients:

Approximately every 6 months, depending on regulatory recommendations and clinical status.

The frequency may vary according to local prescribing guidance.

---

When Should Mavacamten Be Interrupted?

Treatment should be stopped temporarily if:

• LVEF drops below 50%

• Symptomatic heart failure develops

• Significant drug interactions occur

• Pregnancy occurs

Most patients recover ventricular function after interruption.

---

Important Drug Interactions

Exercise caution with:

• Verapamil

• Diltiazem

• Disopyramide

• Strong CYP3A4 inhibitors

• Strong CYP2C19 inhibitors

Combined negative inotropic effects may increase the risk of systolic dysfunction.

Always review the medication list before every dose adjustment.

---

Benefits Demonstrated in Clinical Trials

Major studies have shown that mavacamten can:

• Reduce LVOT gradients

• Improve NYHA functional class

• Increase peak oxygen consumption

• Improve patient-reported quality of life

• Reduce referral for septal myectomy or alcohol septal ablation

These benefits have made mavacamten an important addition to modern HCM management.

---

Practical Clinical Pearls

• Always obtain a high-quality baseline echocardiogram.

• Never ignore declining LVEF.

• Serial echocardiography is mandatory.

• Review medications at every clinic visit.

• Patient education regarding symptoms of heart failure is essential.

• Therapy should be supervised by clinicians experienced in hypertrophic cardiomyopathy.

---

Key Takeaway

Mavacamten represents a major advance in the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Unlike traditional therapies that mainly reduce heart rate or contractility, it directly targets excessive cardiac myosin activity, addressing the disease mechanism itself.

Its remarkable clinical benefits come with one important responsibility—careful monitoring. Regular echocardiographic assessment of LVEF and LVOT gradient remains essential to maximize benefit while preventing systolic dysfunction.

For appropriately selected patients, mavacamten offers the possibility of improved symptoms, better exercise tolerance, enhanced quality of life, and reduced need for invasive septal reduction procedures.

---

References

• 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy.

• ESC Guidelines on Cardiomyopathies.

• EXPLORER-HCM Trial.

• VALOR-HCM Trial.